The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for 4D Molecular Therapeutics Inc is $31.00, about 161.2% above its August 12 closing price of $11.87
Quarterly results
US biotechnology firm's Q2 revenue rose and beat analyst expectations
Q2 net loss and operating income both missed analyst estimates
Company secured $200 mln credit facility from Hercules Capital, with $20 mln initially drawn
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$3.78 mln
$3.10 mln (7 Analysts)
Q2 Net Loss
Miss
$72.94 mln
$70.25 mln (6 Analysts)
Q2 Operating Income
Miss
-$77.03 mln
-$74.25 mln (7 Analysts)
Q2 Loss Per Basic Share
$1.04
Q2 Operating Expenses
$80.81 mln
Outlook and pipeline
Company expects topline data from 4D-150 4FRONT-1 Phase 3 in Q2 2027
FDMT•
